Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
Age
50 - 85 years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Chiba, Japan
Pfizer Investigational Site
Saitama, Japan
Pfizer Investigational Site
Shizuoka, Japan
Pfizer Investigational Site
Tokyo, Japan
Start Date
October 1, 2006
Primary Completion Date
February 1, 2010
Completion Date
February 1, 2010
Last Updated
September 4, 2014
80
ACTUAL participants
bapineuzumab
DRUG
bapineuzumab
DRUG
bapineuzumab
DRUG
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
NCT07178210
NCT04123314
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions